NCT00338182View on ClinicalTrials.gov

AZD1152 in Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

May 23, 2006

Primary Completion Date

June 6, 2008

Study Completion Date

March 1, 2017

Conditions

Tumors

Interventions

DRUG

AZD1152 part A

48-hour continuous intravenous infusion

DRUG

AZD1152 part B

2-hour intravenous infusion

Trial Locations (2)

Unknown

Research Site, Boston

Research Site, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY